ArticleAsian Pacific journal of cancer prevention : APJCP2026
Elevated Liver Enzymes and Genotype I of T. gondii Among Liver Cancer Patients: Evidence of a Potential Link.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveToxoplasma gondii is an intracellular protozoan that may disrupt the traditional cell barriers against cancer, allowing the accumulation of oncogenic mutations over time. Our research aimed to explore the relationship between T. gondii infection and liver cancer development.
methodsThe present study, conducted in the city of Nasiriya, Iraq, involved 80 blood samples collected from individuals aged 18 to 70 years, of both sexes. The samples were divided into two groups: 40 from patients diagnosed with liver cancer and 40 from healthy individuals. All samples were tested using ELISA to detect anti-Toxoplasma gondii antibodies (IgG and IgM).
resultsThe results showed that 21 liver cancer patients and 14 healthy individuals tested positive for T. gondii. Furthermore, liver enzyme levels (ALT, AST, and ALP) were assessed in all participants. The findings revealed a notable elevation in enzyme levels among liver cancer patients co-infected with T. gondii, compared to both non-infected liver cancer patients and the healthy control group. Using PCR, the B1 gene was amplified to confirm infection in selected samples. Ten B1-positive samples (5 from liver cancer and 5 from control) were tested for the GRA6 gene using nested PCR. DNA was extracted with a commercial kit, and amplification was performed using specific primers. Genotyping was conducted via PCR-RFLP targeting the GRA6 gene, using the MseI enzyme to distinguish T. gondii strains based on fragment sizes. RFLP analysis using MseI differentiated genotypes I, II, and III.
conclusionThis study genotyped Toxoplasma gondii in liver cancer patients using nested-PCR and RFLP targeting the GRA6 gene. Genotype I predominated among liver cancer patients, whereas control Genotypes II was predominance in the control group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.